Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Research & Development for 11 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 81.14% year-over-year to -$36.2 million; the TTM figure through Mar 2026 stood at $704.1 million (up 197.67% YoY), while the FY2025 annual figure was $534.8 million, up 49.19% from the prior year.
• Research & Development retreated to -$36.2 million in Q1 2026 per LKFT's latest filing, from $944.4 million in the prior quarter.
• Across five years, Research & Development topped out at $944.4 million in Q4 2025 and bottomed at -$396.8 million in Q3 2025.
• Historically, Research & Development has averaged $122.8 million across 5 years, with a median of -$32.5 million in 2022.
• On a YoY basis, Research & Development climbed as much as 196.58% in 2025 and fell as far as 147.09% in 2025.
• Lakefront Biotherapeutics' Research & Development stood at $382.7 million in 2022, then rose by 14.85% to $439.5 million in 2023, then jumped by 39.49% to $613.1 million in 2024, then soared by 54.04% to $944.4 million in 2025, then plunged by 103.84% to -$36.2 million in 2026.
• Business Quant data shows LKFT's Research & Development at -$36.2 million in Q1 2026, $944.4 million in Q4 2025, and -$396.8 million in Q3 2025.